EntryPoint Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

EntryPoint Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-155	Closed	-$41.4K	–	1671
2024 Q1	$41.4K	Buy	+155	New	+$36.5K	0.04%	851

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EntryPoint Capital's MDGL Position: Q2 2024 in Review

EntryPoint Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2024, closing a stake of 155 shares — an estimated $41.4K sold.

EntryPoint Capital first reported a position in MDGL in Q1 2024 and held it in 1 quarter. The position peaked at $41.4K in Q1 2024. 257 funds tracked by Wall St. Rank hold MDGL as of Q2 2024.

EntryPoint Capital reported no remaining Madrigal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
EntryPoint Capital sold 155 Madrigal Pharmaceuticals shares in Q2 2024, an estimated $41.4K.
EntryPoint Capital first reported a position in Madrigal Pharmaceuticals in Q1 2024 and held it in 1 quarter.
EntryPoint Capital's Madrigal Pharmaceuticals position peaked at $41.4K in Q1 2024.
257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.